Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label safety extension of oral edaravone in ALS (Japan)
jRCT2041200084Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma America
- Start
- Dec 2020
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of edaravone in amyotrophic lateral sclerosis (ALS), sponsored by Mitsubishi Tanabe Pharma America. Primary endpoint: Safety and tolerability. Started Dec 2020; status: completed.
02
Drugs
edaravone
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCT2041200084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041200084.